HC Wainwright Comments on uniQure’s Q1 2023 Earnings (NASDAQ:QURE)

uniQure (NASDAQ:QURE – Get Rating) – Research analysts at HC Wainwright cut their Q1 2023 EPS estimates for shares of uniQure in a note issued to investors on Tuesday, March 7th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of $0.69 for the quarter, down from their prior forecast of $0.82. HC Wainwright currently has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for uniQure’s Q2 2023 earnings at ($0.52) EPS, Q3 2023 earnings at ($1.18) EPS, Q4 2023 earnings at ($0.99) EPS, FY2023 earnings at ($2.00) EPS, FY2024 earnings at ($1.94) EPS, FY2025 earnings at $0.68 EPS, FY2026 earnings at $3.27 EPS and FY2027 earnings at $5.96 EPS.

Other equities research analysts have also issued research reports about the stock. StockNews.com raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Wednesday, March 1st. Credit Suisse Group lifted their price objective on shares of uniQure from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Tuesday, February 28th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $47.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, November 23rd. Guggenheim reaffirmed a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research note on Tuesday, February 28th. Finally, Truist Financial lifted their price objective on shares of uniQure from $51.00 to $65.00 in a research note on Wednesday, November 23rd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.44.

uniQure Stock Down 4.2 %

QURE stock opened at $20.37 on Thursday. The company has a current ratio of 6.28, a quick ratio of 6.19 and a debt-to-equity ratio of 0.22. uniQure has a 1 year low of $12.52 and a 1 year high of $28.25. The company has a fifty day simple moving average of $21.50 and a 200 day simple moving average of $21.14. The firm has a market cap of $956.98 million, a PE ratio of -7.52 and a beta of 1.19.

uniQure (NASDAQ:QURE – Get Rating) last issued its earnings results on Monday, February 27th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.04. The company had revenue of $102.75 million during the quarter, compared to analyst estimates of $55.37 million. uniQure had a negative net margin of 119.07% and a negative return on equity of 26.28%.

Insider Transactions at uniQure

In other news, Director Paula Soteropoulos sold 6,000 shares of the business’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $22.59, for a total transaction of $135,540.00. Following the transaction, the director now owns 16,382 shares in the company, valued at approximately $370,069.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Matthew C. Kapusta sold 2,521 shares of the company’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $21.39, for a total value of $53,924.19. Following the sale, the chief executive officer now owns 468,743 shares of the company’s stock, valued at $10,026,412.77. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Paula Soteropoulos sold 6,000 shares of the company’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $22.59, for a total transaction of $135,540.00. Following the completion of the sale, the director now directly owns 16,382 shares in the company, valued at approximately $370,069.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,919 shares of company stock worth $332,098. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its position in uniQure by 4.0% in the fourth quarter. Arizona State Retirement System now owns 11,867 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 458 shares in the last quarter. Texas Permanent School Fund increased its holdings in shares of uniQure by 2.3% during the second quarter. Texas Permanent School Fund now owns 26,142 shares of the biotechnology company’s stock worth $487,000 after buying an additional 586 shares in the last quarter. Comerica Bank increased its holdings in shares of uniQure by 2.1% during the third quarter. Comerica Bank now owns 29,731 shares of the biotechnology company’s stock worth $549,000 after buying an additional 620 shares in the last quarter. State of Alaska Department of Revenue increased its holdings in shares of uniQure by 3.5% during the third quarter. State of Alaska Department of Revenue now owns 28,470 shares of the biotechnology company’s stock worth $534,000 after buying an additional 975 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in shares of uniQure by 3.4% during the fourth quarter. Exchange Traded Concepts LLC now owns 30,481 shares of the biotechnology company’s stock worth $691,000 after buying an additional 1,016 shares in the last quarter. Institutional investors own 88.03% of the company’s stock.

About uniQure

(Get Rating)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.